Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study

González-Manzano, Ramón; Cid, Joan; Brugarolas, Antonio; Piasecki, C. C.

doi:10.1038/bjc.1995.503

Cited by 4 publications

(1 citation statement)

References 27 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although most of the other immunosuppressive drugs per se may promote tumour cell proliferation [18,19], little is known about the clinical interaction between the different immunosuppressive drugs and adriamycin. Cyclosporine A has been shown to enhance the effect of cytotoxic drugs in a variety of cells [20]; however, when applied in vivo the outcome has been complicated by non‐specific toxicity resulting in severe side‐effects [21]. The effect on the antioxidant regenerating substances in the liver has not yet been studied.…”

Section: Introductionmentioning

confidence: 99%

Adriamycin cytotoxicity may stimulate growth of hepatocellular tumours in an experimental model for adjuvant systemic chemotherapy in liver transplantation

Rissler¹,

Söderdahl²,

Nordman³

et al. 2005

Transplant Int

View full text Add to dashboard Cite

Summary Adjuvant treatment with adriamycin has been suggested to improve results after liver transplantation for hepatocellular cancer. Here we have applied an animal model for evaluation of treatment with adriamycin and/or cyclosporine A on liver tumour growth. Three chemically induced rat liver tumours with various degree of differentiation were transferred to the spleens of syngenic rats. Each recipient group was divided into four subgroups, treated with adriamycin and/or cyclosporine A or none of the drugs. When the tumour was well differentiated no proliferation was found in any of the subgroups. When the tumour exhibited a more pronounced dysplasia, adriamycin stimulated tumour growth. This effect was further increased by cyclosporine. In the animals transplanted with the most aggressive tumour, adriamycin inhibited tumour growth. When given together with cyclosporine this inhibition was counteracted. These data suggest that adriamycin, especially when given together with cyclosporine, may have a stimulatory effect on liver tumour cell growth.

show abstract

Section: Introductionmentioning

confidence: 99%

Adriamycin cytotoxicity may stimulate growth of hepatocellular tumours in an experimental model for adjuvant systemic chemotherapy in liver transplantation

Rissler¹,

Söderdahl²,

Nordman³

et al. 2005

Transplant Int

View full text Add to dashboard Cite

show abstract

Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour

Vrie

Marquet

Eggermont

1997

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

The immunosuppressive drug cyclosporin A has been evaluated recently in phase II trials in cancer therapy as a reverter of P-glycoprotein-mediated multidrug resistance. As an immunosuppressive agent, cyclosporin A potentially can enhance tumour growth. We investigated this potency of cyclosporin A in the weakly immunogenic CC531 colon adenocarcinoma model, using the same dose that had previously been shown to intensify the antitumour activity of doxorubicin in vivo. In vitro cyclosporin A caused no growth acceleration and only in high doses was growth inhibition of CC531 cells observed. In vivo no evidence of growth enhancement was found in short-term assays but, after 4 weeks, rats treated with cyclosporin A had a significantly higher tumour load, mainly consisting of locoregional metastases. These experiments in the CC531 tumour model show that cyclosporin A, used as a reverter of multidrug resistance, may produce short-term improvement of antitumour activity but may also induce enhancement of tumour metastasis.

show abstract

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Leung

Papademetriou

Chang

et al. 2016

Curr Treat Options Gastro

View full text Add to dashboard Cite

As new and effective novel therapies in inflammatory bowel disease (IBD) become available, patients are living longer with advancing age and are at increased risk for malignancy. The management of IBD and malignancy involves multiple combinations of chemotherapy agents and IBD drugs, with the potential for interactions between these therapies. Interactions may either potentiate the effectiveness of drug class or exacerbate their common side effects. In this review article, we present a guide on studied interactions between IBD therapies and chemotherapy agents, specifically those of colorectal cancer, breast cancer, non-Hodgkin's lymphoma, and melanoma. The pharmacology and pharmocokinetics of each IBD drug will be discussed. Then, the IBD drug and chemotherapy interactions are summarized in table format. This guide will provide a quick reference to guide clinicians with this challenging management of two disease processes.

show abstract

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study

Cited by 4 publications

References 27 publications

Adriamycin cytotoxicity may stimulate growth of hepatocellular tumours in an experimental model for adjuvant systemic chemotherapy in liver transplantation

Adriamycin cytotoxicity may stimulate growth of hepatocellular tumours in an experimental model for adjuvant systemic chemotherapy in liver transplantation

Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Contact Info

Product

Resources

About